Decision Operating Systems: The Missing Layer in Drug Development

Decision Operating Systems: the missing layer in drug development.

Drug development has built extraordinary systems for generating evidence. It has rarely built systems for governing what that evidence permits. That gap is where programmes fail.

Over the last decade, drug development has become extraordinarily sophisticated at generating information.

EXISTS

Systems for Discovering Targets

EXISTS

Systems for Designing Molecules

EXISTS

Systems for Discovering Targets

EXISTS

Systems for Discovering Targets

EXISTS

Systems for Discovering Targets

EXISTS

Systems for Discovering Targets

EXISTS

Systems for Discovering Targets

EXISTS

Systems for Discovering Targets

Yet despite this sophistication, one critically important question often remains unanswered:
“Who governs the decision itself? Not the experiment. Not the report. Not the meeting. The decision.”

Where the gap lives

Drug development does not advance through information alone. It advances through commitments.

A target progresses. A molecule advances. A modality receives funding. A CRO is engaged. A board authorises the next tranche of capital.

Each of these represents a decision. Each commits resources. Each changes the future direction of the programme.

Yet in most organisations, those decisions emerge through a combination of scientific enthusiasm, strategic optimism, executive judgement, historical investment, and portfolio pressure.
Sometimes those factors align with evidence. Sometimes they do not.
The challenge is not that organisations lack intelligence. The challenge is that they lack a structured operating layer between evidence and commitment.

Without that layer, nobody explicitly defines what has been established, what remains uncertain, what permission has been earned, what commitment remains prohibited, or what evidence would justify a stop.

Progression slowly becomes an assumption rather than a governed outcome.

The environment progression decisions live inside

Progression decisions do not happen in neutral conditions. They happen inside environments of optimism, sunk cost, strategic pressure, scientific excitement, timeline commitments, investor expectations, and organisational momentum.

When those forces accumulate, continuation becomes the default. Not because the evidence is sufficient. Because the organization has no structured mechanism for determining when evidence becomes permission.

“More information can create more confidence without creating more certainty. Confidence supports a narrative. Certainty requires evidence.”

The industry often assumes that better information leads to better decisions. Sometimes it does. Sometimes it creates more sophisticated reasons to continue investing in programs that have not yet earned continuation.

What is actually at stake

What organizations have systems for

  • How experiments are conducted
  • How vendors deliver work
  • How studies are executed
  • How resources are allocated
  • How portfolios are reviewed

What rarely has a system

  • When evidence becomes permission
  • What blocks progression
  • Who owns the decision
  • What record explains the verdict
  • When to pause, stop, or re-baseline

Every meaningful progression decision consumes resources that cannot easily be recovered: capital, time, organisational attention, vendor capacity, scientific opportunity, strategic flexibility.

Before those resources are committed, organisations should be able to answer one simple question:

What specific evidence has earned the right to proceed? Not what do we believe. Not what do we hope. Not what have we already invested. What has been sufficiently established to justify the next commitment?

Where the industry is heading

Drug development will not be differentiated in the future solely by the ability to generate information. Platforms for generating data, hypotheses, and predictions are proliferating rapidly. The gap is not information volume.

The companies that create the greatest value may not be those that run the most experiments. They may be those that most effectively distinguish between activity and permission.

In drug development, success is rarely determined by the volume of work performed.

It is determined by the quality of the decisions that determine what work deserves to continue.

For leaders across R&D, BD, portfolio strategy, and investment governance:

How does your organization currently determine when evidence becomes permission?

And who owns that decision?

Why Strong Data Does Not Automatically Earn Commitment

Why Strong Data Does Not  Automatically Earn Commitment

Evidence and Commitment are not the same thing. One of the most costly confusions in drug development.

Drug development is built on evidence. Experiments generate data. Studies generate findings. And the assumption seems straightforward:

If the data is strong, the programme should move forward.

Yet some of the most expensive mistakes in drug development occur precisely here — when organisations confuse strong data with progression permission.

The two are not the same thing.

Strong data answers one question: “What have we learned?”

Commitment requires a different question: “What have we earned the right to do next?”

Those questions sound similar. They are fundamentally different. One concerns knowledge. The other concerns commitment.

What data answers

"What have we learned?"
 Concerns knowledge. Belongs to science.

What commitment requires

"What have we earned the right to do next?"Concerns commitment. Belongs to decision-making.

How decision drift happens

Strong data creates confidence. Confidence is valuable. But confidence is not permission.

A programme can inspire confidence while still carrying critical unresolved uncertainties. A molecule can demonstrate activity while still lacking progression readiness. A modality can generate excitement while still lacking the evidence necessary for commitment.

The challenge is not whether the data is good. The challenge is whether the data is sufficient for the decision being requested.

Here is how assumption replaces evidence:

A positive result appears. A milestone is achieved. An expert expresses support.

The conversation shifts from “Should we advance?” to “When do we advance?”

Progression is assumed rather than earned. The organisation has moved from evidence review to expectation management.

Data is visible. Uncertainty is not. Teams can present results and show charts. It is much harder to present what remains unknown – yet unresolved uncertainty often determines whether commitment is appropriate, not the strength of the evidence alone.

The shift that protects programmes

The most important shift organisations can make is moving from a culture of evidence accumulation to a culture of permission clarity.

Not: “How much data do we have?” — But: “What decision does this evidence actually support?”

Not: “Is this finding encouraging?” — But: “What commitment has this finding earned?”

Those questions often produce very different answers.

Drug development does not suffer from a shortage of information. It suffers from a shortage of clarity about what information authorises.

Commitment is not a reward for strong data. Commitment is a decision about future resource allocation.

Evidence creates knowledge. Permission creates progression.

Confusing the two is one of the most expensive mistakes an organisation can make.

For R&D Leaders and Portfolio Teams:

Does your organisation have a formal mechanism for distinguishing what the data shows from what the data authorises? What does that process look like in practice? Share in the comments.